Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 1 Study of ADI-PEG 20 Plus Low Dose Cytarabine in Older Patients With Acute Myeloid Leukemia

NCT02875093 is registered in ClinicalTrials.gov with Polaris Group as lead sponsor.

NCT NCT02875093
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02875093 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 1 Study of ADI-PEG 20 Plus Low Dose Cytarabine in Older Patients With Acute Myeloid Leukemia
Lead sponsor
Polaris Group
Phase
Phase 1
Overall status
Terminated
Start date
January 20, 2017
Completion date
July 10, 2019
Enrollment
23 (actual)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

acute myeloid leukemia